David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles

David L.Lacey辞去主席职务，将继续担任董事会成员并保留委员会领导职务

Current board member Julia P. Gregory unanimously elected new board chair

现任董事会成员Julia P.Gregory一致推选为新的董事会主席

SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L.

2024年5月20日，旧金山（环球通讯社）--Nurix Therapeutics，Inc.（纳斯达克：NRIX），一家临床阶段的生物制药公司，开发用于治疗癌症和炎症性疾病的靶向蛋白质调节药物，今天宣布其董事会主席David L。

Lacey, M.D., stepped down as board chair at the conclusion of today’s annual meeting of stockholders. The board of directors has unanimously elected board member Julia P. Gregory as its new board chair..

在今天的年度股东大会结束时，医学博士莱西辞去了董事会主席的职务。董事会一致选举董事会成员Julia P.Gregory为新的董事会主席。。

Dr. Lacey, who has served on the Nurix board since 2016, and as board chair since 2019, will remain on the board and will continue to serve as chair of its Compensation Committee and as a member of its Development Advisory Committee.

莱西博士自2016年以来一直担任Nurix董事会成员，自2019年以来担任董事会主席，将继续担任董事会薪酬委员会主席和发展咨询委员会成员。

“Nurix is extremely fortunate to have benefited from David’s exceptional guidance as chair over the last five years. His scientific and medical insight has been instrumental in our growth from a private, ligase research company to a public, drug discovery and development company with three innovative programs in clinical development and many drug discovery programs with our collaborators, Gilead, Sanofi and Pfizer,” said Arthur T.

Arthur T.说：“Nurix非常幸运地从David在过去五年担任主席期间的出色指导中受益。他的科学和医学见解有助于我们从一家私人连接酶研究公司成长为一家公共药物发现和开发公司，拥有三个临床开发创新项目，以及与我们的合作者Gilead，Sanofi和Pfizer合作的许多药物发现项目。”。

Sands, M.D., Ph.D., Nurix’s president and chief executive officer. “We are excited to have Julia as our new board chair. Her passion, extensive experience and strategic vision will be invaluable as we accelerate development of our drug programs towards regulatory approval and commercialization with the goal of delivering life changing drugs for patients.”.

桑兹，医学博士，博士，Nurix的总裁兼首席执行官。“我们很高兴有Julia担任我们的新董事会主席。她的热情，丰富的经验和战略愿景将是无价的，因为我们加快了药物计划的发展，以获得监管部门的批准和商业化，为患者提供改变生命的药物。”。

“I have been so incredibly impressed with how Nurix has evolved over my tenure as chair. We have literally turned our scientific theories into drugs that are showing great promise for patients in our clinical trials,” said Dr. Lacey. “As a member of the board, I look forward to continuing to provide my full support to Arthur and his terrific management team, to the full board, and to our dynamic new chair whose expertise is perfect to lead the board through the next phase of Nurix’s growth.

莱西博士说：“在我担任主席期间，Nurix的发展给我留下了非常深刻的印象。我们将科学理论转化为药物，在临床试验中为患者带来了巨大的希望。”。“作为董事会的一员，我期待着继续为Arthur及其出色的管理团队、全体董事会以及我们充满活力的新主席提供全力支持，他们的专业知识非常适合领导董事会度过Nurix下一阶段的成长。

It is indeed with great confidence that I pass the gavel to Julia.”.

我确实满怀信心地把木槌传给了茱莉亚。”。

“I am honored to serve as chair of Nurix’s board and know that I have big shoes to fill,” said Ms. Gregory. “David has been an outstanding board chair and on behalf of the board, I thank him for his leadership. I look forward to continuing to work with David, Arthur, our board colleagues, and Nurix’s management team as we build on our momentum to deliver a new generation of breakthrough drugs for patients.”.

格雷戈里女士说：“我很荣幸能担任Nurix董事会主席，我知道我还有很多事情要做。”。“David一直是一位杰出的董事会主席，我代表董事会感谢他的领导。我期待着继续与David，Arthur，我们的董事会同事和Nurix的管理团队合作，为患者提供新一代突破性药物。”。

Ms. Gregory joined the Nurix board in 2019 and currently serves as the chair of the Audit Committee and as a member of its Nominating and Corporate Governance Committee. Ms. Gregory is currently Chair and Chief Executive Officer of Isometry Advisors, Inc., a biotechnology financial, strategy, and management advisory firm.

Gregory女士于2019年加入Nurix董事会，目前担任审计委员会主席及其提名和公司治理委员会成员。格雷戈里女士目前是Isometry Advisors，Inc.的董事长兼首席执行官。Isometry Advisors，Inc.是一家生物技术财务、战略和管理咨询公司。

Ms. Gregory formerly served as Chief Executive Officer and a member of the board of ContraFect Corporation, a biotechnology company focused on therapeutics for drug resistant infectious diseases. Prior to her appointment as Chief Executive Officer, Ms. Gregory served as ContraFect’s Executive Vice President and Chief Financial Officer.

格雷戈里女士曾担任ContraFect Corporation的首席执行官和董事会成员，ContraFect Corporation是一家专注于抗药性传染病治疗的生物技术公司。在被任命为首席执行官之前，格雷戈里女士曾担任ContraFect的执行副总裁兼首席财务官。

Earlier in her career, Ms. Gregory served as President and Chief Executive Officer of Five Prime Therapeutics, Inc., and as Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. In addition, Ms. Gregory has twenty years of investment banking experience, including at Dillon, Read & Co.

在职业生涯的早期，格雷戈里女士曾担任Five Prime Therapeutics，Inc.的总裁兼首席执行官，以及Lexicon Pharmaceuticals，Inc.的执行副总裁、企业发展和首席财务官。此外，格雷戈里女士拥有二十年的投资银行业经验，包括在Dillon，Read＆Co。

and at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice. Ms. Gregory currently serves on the board of directors of Biohaven Ltd. Ms. Gregory holds a B.A. from George Washington University and an M.B.A. from the Wharton School at the University of Pennsylvania..

在朋克齐格尔公司（Punk，Ziegel&Company），她曾担任投资银行业务主管及其生命科学业务主管。格雷戈里女士目前担任生物港有限公司董事会成员。格雷戈里女士拥有乔治华盛顿大学的学士学位和宾夕法尼亚大学沃顿商学院的工商管理硕士学位。。

About Nurix

关于Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases.

Nurix Therapeutics是一家临床阶段的生物制药公司，专注于基于细胞蛋白水平调节的创新小分子和抗体疗法的发现，开发和商业化，作为癌症，炎症和其他具有挑战性疾病的新型治疗方法。

Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels.

Nurix利用E3连接酶的广泛专业知识以及专有的DNA编码文库，建立了DELigase，一个综合发现平台，以鉴定和推进针对E3连接酶的新型候选药物，E3连接酶是一类可以调节细胞内蛋白质的广泛酶。Nurix的药物发现方法是利用或抑制泛素-蛋白酶体系统中E3连接酶的天然功能，以选择性地降低或增加细胞蛋白水平。

Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cell and NK cells.

Nurix全资拥有的临床阶段管道包括布鲁顿酪氨酸激酶（一种B细胞信号蛋白）的靶向蛋白降解物和Casitas B谱系淋巴瘤原癌基因B的抑制剂，Casitas B谱系淋巴瘤原癌基因B是一种E3连接酶，可调节多种免疫细胞类型的激活，包括T细胞和NK细胞。

Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com..

Nurix总部位于加利福尼亚州旧金山。有关更多信息，请访问http://www.nurixtx.com..

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

本新闻稿包含《1995年美国私人证券诉讼改革法案》和其他联邦证券法所指的前瞻性声明。本文中包含的任何不描述历史事实的陈述都是前瞻性陈述，涉及风险和不确定性，可能导致实际结果与此类前瞻性陈述中讨论的结果存在重大差异。

Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended February 29, 2024, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price.

这些风险和不确定性包括Nurix截至2024年2月29日的10-Q表季度报告中“风险因素”标题下描述的风险，以及随后向SEC提交的文件。任何这些风险和不确定性都可能对Nurix的业务和经营成果产生重大不利影响，进而可能对Nurix的股价产生重大不利影响。

Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events..

Nurix提醒您不要过度依赖任何前瞻性陈述，这些陈述仅在做出之日起生效。Nurix没有义务公开更新任何前瞻性声明，以反映新信息、事件或情况，或反映意外事件的发生。。

Contacts:

联系人：

Investors

投资者

Jason Kantor, Ph.D.

Jason Kantor博士。

Nurix Therapeutics

Nurix治疗学

ir@nurixtx.com

ir@nurixtx.com

Elizabeth Wolffe, Ph.D.

伊丽莎白·沃尔夫博士。

Wheelhouse Life Science Advisors

驾驶室生命科学顾问

lwolffe@wheelhouselsa.com

lwolffe@wheelhouselsa.com

Media

媒体

Aljanae Reynolds

Aljanae Reynolds

Wheelhouse Life Science Advisors

驾驶室生命科学顾问

areynolds@wheelhouselsa.com

areynolds@wheelhouselsa.com